Q3 2026 results · 30 October 2026

Cancer medicines now bring in 48% of AstraZeneca's $16.2bn revenue.

$7.8Bcancer medicine revenue, up 17% at CER

$16.2Btotal revenue, up 7% at CER

$1.6BFarxiga, down 25% after patent loss

Source

Get a note when AstraZeneca reports next.

Whatco sends a short notification with the number that matters, and the full story of the company is a tap away.